Rate-Control Treatment and Mortality in Atrial Fibrillation

• Published in: Circulation (New York, N.Y.) Vol. 132; no. 17; pp. 1604 - 1612
• Main Authors: Chao, Tze-Fan, Liu, Chia-Jen, Tuan, Ta-Chuan, Chen, Su-Jung, Wang, Kang-Ling, Lin, Yenn-Jiang, Chang, Shih-Lin, Lo, Li-Wei, Hu, Yu-Feng, Chen, Tzeng-Ji, Chiang, Chern-En, Chen, Shih-Ann
• Format: Journal Article
• Language: English
• Published: United States by the American College of Cardiology Foundation and the American Heart Association, Inc 27.10.2015
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Aged; Aged, 80 and over; Anti-Arrhythmia Agents - therapeutic use; Anticoagulants - therapeutic use; Atrial Fibrillation - drug therapy; Atrial Fibrillation - mortality; Atrial Fibrillation - physiopathology; Calcium Channel Blockers - therapeutic use; Cause of Death; Cohort Studies; Comorbidity; Confounding Factors (Epidemiology); Digoxin - therapeutic use; Drug Utilization; Female; Heart Rate - drug effects; Humans; Income; Male; Middle Aged; Practice Guidelines as Topic; Proportional Hazards Models; Residence Characteristics; Risk Reduction Behavior; Taiwan - epidemiology; Taiwan; adrenergic beta antagonists; atrial fibrillation; heart rate; digoxin; calcium channel blockers

BACKGROUND—Current American and European guidelines emphasize the importance of rate-control treatments in treating atrial fibrillation with a Class I recommendation, although data on the survival benefits of rate control are lacking. The goal of the present study was to investigate whether patients...